Autres langues Mangalam Drugs & Organics Limited NSE India S.E.

Actions

MANGALAM

INE584F01014

Produits pharmaceutiques

Marché Fermé - NSE India S.E. 13:05:09 17/08/2026			Varia. 5j.	Varia. 1 janv.
27,84 ^INR	-0,82%		+2,05%	+1,20%

12/08	Mangalam Drugs & Organics Limited publie ses résultats pour le premier trimestre clos le 30 juin 2026	CI
17/06	Mangalam Drugs and Organics Ltd. en défaut de paiement auprès de la Bank of Baroda et de la Bank of Maharashtra	CI

Autres langues

12/08	Mangalam Drugs & Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2026
17/06	Mangalam Drugs and Organics Ltd. Defaults on Loan Obligations to Bank of Baroda and Bank of Maharashtra
14/05	Mangalam Drugs & Organics Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026
17/04	Mangalam Drugs & Organics Limited Announces Resignation of Anuradha Pandey as Company Secretary & Compliance Officer, Effective March 29, 2026
16/04	Mangalam Drugs and Organics Limited Defaults on Loan Obligations Exceeding 30 Days with INR 95.197 Million to Bank of Maharashtra and INR 60.608 Million to Bank of Baroda
26/03	Mangalam Drugs and Organics Limited Appoints Shweta Patel as Company Secretary & Compliance Officer, Effective April 1, 2026
17/03	Mangalam Drugs and Organics Limited Reports Loan Defaults Exceeding 30 Days on Bank Borrowings
17/03	Mangalam Drugs and Organics Limited Defaults on Loan Obligations to Bank of Maharashtra and Bank of Baroda
17/03	Mangalam Drugs and Organics Limited Defaults on Bank Loan Obligations Exceeding 30 Days with INR 70.705 Million to Bank of Maharashtra and INR 44.677 Million to Bank of Baroda
17/03	Mangalam Drugs and Organics defaults on loan obligations to Bank of Baroda, Bank of Maharashtra
06/02	Mangalam Drugs and Organics names Jeevan M. Dalvi as CFO
06/02	Mangalam Drugs and Organics Limited Approves the Appointment of Jeevan Mukund Dalvi as Chief Financial Officer, Effective February 6, 2026
17/01	Mangalam Drugs and Organics Limited Announces Resignation of Rukmesh P. Dhandhania as Independent Director and Member of Audit and Nomination and Remuneration Committees, Effective January 16, 2026
15/01	Mangalam Drugs & Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025
15/01	Mangalam Drugs and Organics Limited Approves Resignation of Ajay A. Samant as Chief Financial Officer, Effective January 31, 2026
15/01	Mangalam Drugs and Organics Limited Announces Executive Changes
25/11	Mangalam Drugs and Organics gets order worth 150 million rupees
25/11	Mangalam Drugs & Organics Gets INR150 Million Repeat Export Order for Anti-Malarial API
25/11	Mangalam Drugs and Organics Limited Receives Significant Repeat Export Order for Anti-Malarial API from One of Its Reputed International Clients
20/11	Mangalam Drugs & Organics Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025
18/11	Mangalam Drugs & Organics Limited Announces Default on Its Loan Obligations
22/08/25	Indian Equities Fall on Friday as IT Stocks Weigh Ahead of Powell's Jackson Hole Speech
22/08/25	Mangalam Drugs & Organics Secures Export Order Worth Over $2 Million; Shares Jump 4%
22/08/25	Mangalam Drugs and Organics receives export order valued at $2.2 million
22/08/25	Mangalam Drugs & Organics Limited Receives Significant Repeat Export Order from One of Its Reputed International Clients